Fisher Asset Management LLC Has $36.74 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Fisher Asset Management LLC reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 2.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 119,865 shares of the company's stock after selling 3,241 shares during the quarter. Fisher Asset Management LLC owned about 0.39% of Medpace worth $36,742,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of MEDP. Victory Capital Management Inc. grew its holdings in Medpace by 21.5% during the fourth quarter. Victory Capital Management Inc. now owns 68,657 shares of the company's stock worth $21,045,000 after acquiring an additional 12,127 shares during the period. Norden Group LLC increased its holdings in Medpace by 207.8% in the fourth quarter. Norden Group LLC now owns 5,014 shares of the company's stock valued at $1,537,000 after buying an additional 3,385 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Medpace by 38.0% during the 4th quarter. Van ECK Associates Corp now owns 8,205 shares of the company's stock worth $2,515,000 after acquiring an additional 2,258 shares in the last quarter. Retirement Systems of Alabama grew its holdings in shares of Medpace by 0.3% in the 4th quarter. Retirement Systems of Alabama now owns 62,106 shares of the company's stock worth $19,037,000 after acquiring an additional 204 shares during the period. Finally, Alliance Wealth Advisors LLC UT increased its stake in Medpace by 4.7% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 2,896 shares of the company's stock valued at $888,000 after purchasing an additional 131 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Robert W. Baird raised their price target on Medpace from $446.00 to $454.00 and gave the company an "outperform" rating in a research report on Wednesday, April 24th. StockNews.com upgraded shares of Medpace from a "hold" rating to a "buy" rating in a research report on Tuesday, April 23rd. UBS Group raised Medpace from a "neutral" rating to a "buy" rating and upped their target price for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research report on Monday, March 18th. They set a "hold" rating and a $395.00 price target for the company. Finally, Guggenheim increased their price objective on Medpace from $453.00 to $464.00 and gave the company a "buy" rating in a research note on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Medpace has a consensus rating of "Moderate Buy" and a consensus price target of $443.00.

Insider Buying and Selling

In other news, major shareholder Medpace Investors, Llc sold 13,988 shares of Medpace stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total value of $5,404,823.32. Following the transaction, the insider now directly owns 5,525,959 shares of the company's stock, valued at approximately $2,135,175,298.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, major shareholder Medpace Investors, Llc sold 13,988 shares of the firm's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the transaction, the insider now owns 5,525,959 shares of the company's stock, valued at approximately $2,135,175,298.01. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 102 shares of the company's stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares of the company's stock, valued at $6,117,943. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 204,442 shares of company stock valued at $82,702,867. 20.30% of the stock is currently owned by company insiders.

Medpace Stock Performance

NASDAQ MEDP traded up $1.50 during trading hours on Friday, hitting $392.57. 133,312 shares of the company's stock were exchanged, compared to its average volume of 261,284. The firm has a market capitalization of $12.16 billion, a P/E ratio of 40.02, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40. The business's 50 day moving average is $398.08 and its 200-day moving average is $331.78. Medpace Holdings, Inc. has a 12-month low of $197.39 and a 12-month high of $421.00.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.45 by $0.75. The firm had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. Medpace's revenue was up 17.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.27 earnings per share. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.